These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer. Okegawa T; Nutahara K; Higashihara E J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699 [TBL] [Abstract][Full Text] [Related]
23. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer. Morris WJ; Keyes M; Palma D; Spadinger I; McKenzie MR; Agranovich A; Pickles T; Liu M; Kwan W; Wu J; Berthelet E; Pai H Urology; 2009 Apr; 73(4):860-5; discussion 865-7. PubMed ID: 19168203 [TBL] [Abstract][Full Text] [Related]
24. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy? Pai HH; Eldridge B; Bishop D; Alexander A; Lesperance M; Blood P; Lim J; Ludgate C Can J Urol; 2009 Apr; 16(2):4541-52. PubMed ID: 19364426 [TBL] [Abstract][Full Text] [Related]
25. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136 [TBL] [Abstract][Full Text] [Related]
26. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer. Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198 [TBL] [Abstract][Full Text] [Related]
27. Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE. Elliott SP; Meng MV; Elkin EP; McAninch JW; Duchane J; Carroll PR; J Urol; 2007 Aug; 178(2):529-34; discussion 534. PubMed ID: 17570425 [TBL] [Abstract][Full Text] [Related]
28. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer. Heymann JJ; Benson MC; O'Toole KM; Malyszko B; Brody R; Vecchio D; Schiff PB; Mansukhani MM; Ennis RD J Clin Oncol; 2007 Jan; 25(1):77-84. PubMed ID: 17194907 [TBL] [Abstract][Full Text] [Related]
29. Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy. Higgins GS; McLaren DB; Kerr GR; Elliott T; Howard GC Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):982-9. PubMed ID: 16750310 [TBL] [Abstract][Full Text] [Related]
30. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study. Ares C; Popowski Y; Pampallona S; Nouet P; Dipasquale G; Bieri S; Ozsoy O; Rouzaud M; Khan H; Miralbell R Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):656-63. PubMed ID: 19250768 [TBL] [Abstract][Full Text] [Related]
31. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426 [TBL] [Abstract][Full Text] [Related]
32. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266 [TBL] [Abstract][Full Text] [Related]
33. Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation dose. Williams S; Buyyounouski M; Kestin L; Duchesne G; Pickles T Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):724-31. PubMed ID: 20472361 [TBL] [Abstract][Full Text] [Related]
34. [Surgical and medical treatment for localized prostate cancer]. Kawai K Gan To Kagaku Ryoho; 2007 Jul; 34(7):1002-5. PubMed ID: 17637535 [TBL] [Abstract][Full Text] [Related]
35. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. Eggener SE; Roehl KA; Yossepowitch O; Catalona WJ J Urol; 2006 Oct; 176(4 Pt 1):1399-403. PubMed ID: 16952643 [TBL] [Abstract][Full Text] [Related]
36. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T; Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219 [TBL] [Abstract][Full Text] [Related]
37. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation. Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527 [TBL] [Abstract][Full Text] [Related]
38. Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins. Choo R; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw DA; Cheung P; Pearse M Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):407-12. PubMed ID: 19211197 [TBL] [Abstract][Full Text] [Related]
39. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy. Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):669-77. PubMed ID: 16682149 [TBL] [Abstract][Full Text] [Related]
40. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Dattoli M; Wallner K; True L; Cash J; Sorace R Cancer; 2007 Aug; 110(3):551-5. PubMed ID: 17577217 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]